Audio-Described Menopause Education Program in Visually Impaired Women
17 août 2026 mis à jour par: İlknur Münevver Gönenç, Ankara University
The Effect of Education Provided Through Audio Description Method on Menopause Knowledge and Menopausal Symptoms in Visually Impaired Women: Randomized Controlled Trial
This randomized controlled trial was conducted to evaluate the effect of an audio-described menopause education program on menopause knowledge and menopausal symptoms in women with visual impairment.
A total of 46 women who were members of the Ankara Branch of the Altı Nokta Blind Association were randomly assigned to either an intervention group (n=23) or a control group (n=23).
The intervention group received an accessible menopause education program, while the control group did not receive the intervention during the study period.
Outcomes included menopause knowledge and menopausal symptom severity, assessed using standardized measurement tools.
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Description détaillée
This study was designed as a randomized controlled trial in accordance with CONSORT guidelines. It aimed to determine the effectiveness of an audio-described menopause symptom and awareness education program for women with visual impairment on menopause knowledge and menopausal symptoms.
The study sample consisted of 46 women who were members of the Ankara Branch of the Altı Nokta Blind Association. Participants were randomly allocated in a 1:1 ratio to either the intervention group (n=23) or the control group (n=23).
Data were collected using a demographic information form, the Menopause Knowledge Scale, and the Menopause Rating Scale. The intervention group received an audio-described educational program designed to improve accessibility for women with visual impairment, while the control group did not receive the intervention during the study period.
Statistical analyses included descriptive statistics, Fisher-Freeman-Halton Exact test, Pearson chi-square test, Cronbach's alpha reliability analysis, assessment of skewness and kurtosis for normality, Pearson correlation analysis, independent samples t-test, and analysis of covariance (ANCOVA). Statistical significance was set at p < 0.05.
Type d'étude
Interventionnel
Inscription (Réel)
46
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Altindağ
-
Ankara, Altindağ, Turquie (Türkiye), 06250
- Ankara University
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
Accepte les volontaires sains
Non
La description
Inclusion Criteria:
- Being a member of the Ankara Branch of the Altı Nokta Blind Association,
- Being a woman with visual impairment (congenital or acquired),
- Being female,
- Being between 40 and 60 years of age,
- Being able to speak Turkish,
- Having no additional communication problems other than visual impairment,
- Having experienced at least 12 months of amenorrhea (STRAW+1 criteria).
Exclusion Criteria:
- Refusal to participate in the study,
- Previous participation in a structured menopause-related education program,
- Use of pharmacological treatment for the management of menopausal symptoms,
- Use of non-pharmacological methods for menopausal symptom management (e.g., yoga, aromatherapy, phytotherapy, etc.),
- Surgical menopause,
- Having additional disabilities other than visual impairment (hearing, intellectual, or physical disabilities).
Withdrawal / Discontinuation Criteria
- Initiation of any pharmacological or non-pharmacological intervention aimed at reducing menopausal symptoms during the study period,
- Non-adherence to the study protocol,
- Voluntary withdrawal from the study.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Audio description-based menopause education program
Participants in this arm received an audio-described menopause education program designed for women with visual impairment.
The intervention aimed to improve menopause knowledge and reduce menopausal symptom-related difficulties.
The educational content was delivered in an accessible format tailored to participants' needs.
Outcomes were assessed using standardized measurement tools.
|
This intervention consisted of a structured audio-described menopause education program developed for women with visual impairment.
The program provided accessible information about menopause, menopausal symptoms, and symptom management strategies to improve knowledge and awareness.
|
|
Aucune intervention: Standard of care
Participants in this arm did not receive the audio-described menopause education program during the study period.
They continued with their usual daily life without any structured educational intervention related to menopause.
Outcomes were assessed at the same time points using standardized measurement tools.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Menopause Knowledge
Délai: Measured at three time points: baseline (pre-test), immediately after the intervention (T1), and 1 month post-intervention (T2).
|
To assess changes in menopause knowledge following the audio-described menopause education program.
The total score of the "Menopause Knowledge Scale" ranges from 14 to 70, with higher scores indicating a higher level of overall knowledge about menopause.
Similarly, higher scores on the General Menopause Knowledge subscale (5-25) and the Knowledge of Menopausal Symptoms and Management subscale (9-45) indicate greater knowledge in the respective domains.
|
Measured at three time points: baseline (pre-test), immediately after the intervention (T1), and 1 month post-intervention (T2).
|
|
Menopausal Symptom Severity
Délai: Measured at three time points: baseline (pre-test), immediately after the intervention (T1), and 1 month post-intervention (T2).
|
To evaluate changes in menopausal symptom severity following the audio-described menopause education program.
The Menopause Rating Scale was used to assess the severity of menopausal symptoms.The total score of the scale ranges from 0 to 44.
Higher total scores indicate greater severity of menopausal symptoms and a more negative impact on quality of life.
|
Measured at three time points: baseline (pre-test), immediately after the intervention (T1), and 1 month post-intervention (T2).
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
15 février 2025
Achèvement primaire (Réel)
15 juillet 2025
Achèvement de l'étude (Réel)
15 juillet 2025
Dates d'inscription aux études
Première soumission
3 juillet 2026
Première soumission répondant aux critères de contrôle qualité
17 août 2026
Première publication (Réel)
19 août 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
19 août 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
17 août 2026
Dernière vérification
1 août 2026
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- Ankara University Thesis
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
OUI
Description du régime IPD
De-identified participant data, including baseline characteristics and outcome measures, will be shared.
No identifiable personal data will be included.
Délai de partage IPD
De-identified individual participant data will be available beginning 6 months after publication of the study results and will remain available for 5 years.
Critères d'accès au partage IPD
Access to individual participant data and supporting documents will be granted to qualified researchers who submit a methodologically sound research proposal.
Requests must be approved by the principal investigator or study sponsor.
Data will be provided for non-commercial academic research purposes only.
All data will be de-identified, and no personally identifiable information will be shared.
Data will be shared via secure electronic transfer upon approval.
Type d'informations de prise en charge du partage d'IPD
- SÈVE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .